Iovance Posts Record Q2 Revenue of ~$99M, Gross Margin Hits 56%, and FDA Grants Fast Track for Lifileucel in Sarcomas
IOVA has more than doubled off its 52-week low of $1.76.
Summary
Iovance reported record Q2 2026 revenue of ~$99M, a 66% increase, with gross margin reaching 56%. The company is reviewing its full-year guidance upward and announced FDA Fast Track for lifileucel in soft tissue sarcomas. Cash of ~$304M funds operations into 2H28.
Key Events · Earnings and Guidance · IOVA
-
Record Q2 Revenue
Total product revenue reached ~$99M, up 66% from ~$60M in Q2 2025, driven by U.S. Amtagvi sales of ~$91M.
-
Gross Margin Expansion
Gross margin improved to 56%, reflecting higher sales volume, cost optimization, and manufacturing efficiencies.
-
Guidance Under Review
Based on strong Q2 performance, Iovance is reviewing its FY2026 revenue guidance of $350M-$370M and will provide an update in Q3.
-
FDA Fast Track for Sarcomas
FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas, supporting the registrational SARATOGA trial in UPS and DDLPS.
Analysis · IOVA · Life Sciences
Iovance delivered its strongest quarter yet, with Amtagvi driving U.S. revenue to ~$91M and total revenue up 66% year-over-year. Gross margin jumped to 56%, reflecting manufacturing efficiencies and cost discipline. The company is reviewing its full-year guidance of $350M-$370M, signaling potential upside. FDA Fast Track designation for lifileucel in soft tissue sarcomas opens a new registrational path, while a cash runway into 2H28 removes near-term financing risk. This quarter marks a turning point toward profitability and pipeline expansion.
At the time of this filing, IOVA was trading at $4.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $1.76 to $5.64. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.